It comes days after the drugmaker announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.
Preliminary results show CoronaVac triggered a quick immune response but level of antibodies were lower than in people who had recovered from the disease.
A final analysis of the Phase 3 trial of Pfizer's coronavirus vaccine shows it was 95 per cent effective in preventing infections.
Pfizer's vaccine candidate was shown to be more than 90% effective in preventing COVID-19 based on initial data, but the company faces distribution and storage challenges.
A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective.
BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates."
Although Pfizer's coronavirus vaccine data looks promising, experts say we should remain 'cautious' as the full data has still not been released.
Pfizer cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.
Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.